New study tracks Dacomitinib's Real-World impact on lung cancer
NCT ID NCT06321510
First seen Apr 07, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This study observes how patients with advanced non-small cell lung cancer and a specific gene mutation (EGFR-positive) respond to the drug dacomitinib in real-world settings in Taiwan. It includes 29 adults who took dacomitinib as their first treatment. Researchers track dosage changes, side effects, and how long patients live or stay cancer-free. The goal is to understand the drug's effectiveness and safety outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tri-Service General Hospital
Taipei, 11490, R.O.C., Taiwan
Conditions
Explore the condition pages connected to this study.